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Background: The use of computerized systems to support evidence-based practice is commonplace in
contemporary medicine. Despite the prolific use of electronic support systems there has been relatively little
research on the uptake of web-based systems in the oncology setting. Our objective was to examine the uptake of
a web-based oncology protocol system (www.eviq.org.au) by Australian cancer clinicians.
Methods: We used web-logfiles and Google Analytics to examine the characteristics of eviQ registrants from
October 2009-December 2011 and patterns of use by cancer clinicians during a typical month.
Results: As of December 2011, there were 16,037 registrants; 85% of whom were Australian health care
professionals. During a typical month 87% of webhits occurred in standard clinical hours (08:00 to 18:00 weekdays).
Raw webhits were proportional to the size of clinician groups: nurses (47% of Australian registrants), followed by
doctors (20%), and pharmacists (14%). However, pharmacists had up to three times the webhit rate of other clinical
groups. Clinicians spent five times longer viewing chemotherapy protocol pages than other content and the
protocols viewed reflect the most common cancers: lung, breast and colorectal.
Conclusions: Our results demonstrate eviQ is used by a range of health professionals involved in cancer treatment
at the point-of-care. Continued monitoring of electronic decision support systems is vital to understanding how
they are used in clinical practice and their impact on processes of care and patient outcomes.
Keywords: Clinical decision support systems, Evidence-based practice, Cancer chemotherapy protocols, Clinical
oncology, Health personnelBackground
The medical evidence-base is increasing exponentially,
making it virtually impossible for individual healthcare
professionals to maintain an up-to-date and comprehen-
sive knowledge of their field of practice [1-4]. In an at-
tempt to address this problem, professional bodies and
healthcare organizations have invested in the develop-
ment of evidence-based resources that are available elec-
tronically. Like many other specialties, oncology practice
has taken advantage of the growing use of web-based
technology by developing online guideline and protocol
systems. These have been developed across multiple* Correspondence: sallie.pearson@sydney.edu.au
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reproduction in any medium, provided the orjurisdictions but originate mostly from North America
and Europe [5].
Electronic decision support has the capacity to im-
prove the processes of care and patient outcomes in on-
cology practice. But the provision of computer support
does not guarantee uptake, and utilization of systems at
the point-of-care is crucial if systems are to improve the
quality of clinical practice [6]. Despite the growing num-
ber of web-based oncology systems around the globe,
there has been limited evaluation of the use and impact
of electronic support systems in the cancer treatment
setting. However, there is some evidence demonstrating
electronic oncology systems are adopted readily by clini-
cians and are seen as integral in cancer treatment deliv-
ery [7]. Moreover, they have been shown to increasel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing errors and adverse events [8-12].
In this article we focus specifically on an Australian
web-based protocol system, eviQ (previously known as
CI-SCaT). eviQ is a web-based repository of nearly 1,300
peer-reviewed cancer treatment protocols managed under
the auspices of the Cancer Institute New South Wales
(NSW) [https://www.eviq.org.au/]. The system underwent
a major rebuild and rebranding in 2009 to better meet the
specific needs of oncologists, nurses, primary health care
physicians, pharmacists, and patients. Evaluations of the
system to date have been primarily qualitative, with a
focus on barriers to use at the point-of-care [11,12]. How-
ever, the new platform increases opportunities to conduct
longitudinal quantitative research based on web-logfile
analysis. As such, the aim of this study is to describe the
patterns of eviQ use by clinicians practising in the Austra-
lian healthcare setting.Methods
Study design
This is a study of web-logfiles generated from eviQ over
a 26-month period. The study period coincides with the
launch of the new platform in October 2009 and covers
the first two years of operation until December 2011.
The previous platform (CI-SCaT) was taken offline on
March 31 2010 to allow sufficient opportunity for users
to transition and register on the eviQ website.Study setting
In Australia, oncology protocols are delivered primarily
in the ambulatory care (outpatient) setting at metropol-
itan hospitals (university-affiliated, tertiary referral cen-
ters covering geographic areas of around 75 square
kilometers), regional centers (with catchments up to
1,200 square kilometers) and rural hospitals (with catch-
ments up to 3,400 square kilometers).
eviQ is managed by the Cancer Institute NSW, a gov-
ernment funded agency established to improve cancer
control in Australia’s largest state, NSW. eviQ primarily
targets health professionals involved in implementing
cancer care by providing detailed and extensive instruc-
tions on how to deliver evidence-based treatments safely
and appropriately. Treatment information encompasses
adolescent and young adult care, cancer genetics,
haematology, haemapoietic progenitor cell transplants,
medical oncology, nursing, primary health, palliative care
and radiation oncology. The site comprises over 1,300
protocols, developed by a consensus process involving
specialist physicians, nurses, pharmacists and allied
health practitioners from across Australia. Each protocol
undergoes a comprehensive review every 1 to 2 years.
While the primary eviQ target audience is healthprofessionals, the site also publishes information tailored
specifically to cancer patients and their carers.
Data sources and analysis
For the purposes of this evaluation we used two data
sources, both of which have different capabilities in
terms of understanding eviQ use. Outputs from both
data sources were converted to Microsoft excel 2010 for-
mat for analysis. We report demographic variables for
all registrants at the end of our study period (December
31 2011) and patterns of use during a typical month
based on eviQ logfiles. For the latter, we examined rates
of use across the last three months of the study period
(October through December, 2011). Rates of overall use
were lowest in December (1,145 hits/100 registrants)
most probably due to the holiday period, but were com-
parable in October (1,499 hits/100 registrants) and
November (1,418 hits/100 registrants). We selected
October 2011 to represent a ‘typical’ month and all sub-
sequent analyses focused exclusively on this period.
eviQ platform
The eviQ secretariat provided the research team with ac-
cess to de-identified data from the eviQ platform. Demo-
graphic registrant and logfile data were obtained on-site
at the Cancer Institute NSW in unit record format
(stripped of personal identifiers such as usernames). The
eviQ platform has the capacity to generate data on the
characteristics of all registered users including registrant
type (individual clinician or unit registration), health set-
ting (primary care or hospital), health sector (public, pri-
vate, or both), geographical location of practice, clinician
group, years of oncology experience, and source of refer-
ral to the eviQ website. This information is reported by
users upon registration and website registrants are
prompted to update this information on an annual basis.
Further, logfiles also monitor webhits, defined as one
click anywhere on the eviQ website, that can be strati-
fied by any of the aforementioned variables (e.g., clin-
ician type, years of oncology experience) and the time
at which the webhits occur (e.g., time of day, month,
year). However, the current eviQ logfile reports are
aggregated and do not have the capacity to determine
the content accessed according to health professional
groups.
As such, we report on the following:
Registrant characteristics
We report the characteristics of individuals and units
identifying themselves as Australian health
professionals upon site registration. We report the
number of new health professional registrations by
month for the period October 2009 to December 2011
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the end of the study period.
Patterns of eviQ use
We examined webhits during standard clinic hours
(Monday to Friday between 08:00–18:00) compared
with use outside clinic hours. This approach has been
used previously in logfile analyses as a proxy for point-
of-care use in Australian clinical practice [13].
Moreover, the majority of chemotherapy and
radiotherapy cancer treatments are delivered during
these times.
We stratified our analysis by registrant type (individual
or unit registration), individual clinician group
(medical, nursing, pharmacy and radiation therapists)
and years of oncology experience. As is standard in
logfile analysis, we report both the volume of webhits
and hits/100 website registrants [14].
Google analytics
The eviQ secretariat provided the research team with ac-
cess to their Google Analytics profile from which we
extracted data of interest. Google Analytics’ reports pro-
vide data on website traffic and allows for the examin-
ation of the intensity of eviQ use for all registrants
including number of visits and unique visits to eviQ. A
visit is defined as a registrant logging on to eviQ for up
to four hours, unless the registrant terminates their visit
by logging off or leaving the website. Google Analytics
produces aggregated data relating to typical user sessions
including number of pages accessed and time spent on
eviQ during a typical visit for a defined period (e.g., visits
in a typical week or month). Google Analytics also has
the capacity to provide data on content accessed and
time spent on specific eviQ pages (e.g., time spent on a
particular chemotherapy protocol page).
Data from Google Analytics does not distinguish be-
tween different user groups (e.g., health professionals’ vs.
consumers), limiting the capacity to undertake analyses
on how different groups access eviQ. However, given
that health professionals comprise 92% (n = 14,800) of
eviQ registrants, Google Analytics output will be
heavily influenced by patterns of use by health pro-
fessionals.
Using this data source, we report on the following dur-
ing a typical month (October 2011):
Typical user sessions
We report the total number of eviQ visits, average
number of pages/visit, average visit duration, and mode
of access (mobile device or computer). Google
Analytics output is averaged across all users such thatwe cannot calculate descriptive statistics such as
median and range for these data.
Content accessed
We report the top 100 pages accessed and time spent
on these pages. The top 100 pages were grouped
according to their content into the following categories:
login/registration; transition pages (such as tabs
directing users to specific content); and cancer
treatment content pages (chemotherapy protocols or
supportive treatment information). We used the time
spent on each of the 100 pages to calculate the range
and median time spent on pages according to the
abovementioned categories. To better understand the
range of clinical content accessed by eviQ users, we
also conducted an analysis of the top 100 cancer
treatment content pages (excluding all login,
registration, and transition pages). We present total,
median and range of page views according to the
following categories: medical oncology, haematology,
radiation oncology, and supportive treatment
information.
Ethics
Ethics approval to monitor eviQ utilization using eviQ
web-logfiles and Google Analytics was obtained from
the NSW Population and Health Services Research Eth-
ics committee (approval number HREC/10/CIPHS/70).
Results
Registrant characteristics
At December 31, 2011 there were 16,037 eviQ regis-
trants, the majority of whom identified themselves
as Australian health professionals (85.5%, n = 13,711),
followed by consumers (7.7%, n = 1,237), and health pro-
fessionals practising outside Australia (6.7%, n = 1,089).
Australian health professionals were registered as indi-
viduals (92.4%, n = 12,688) or units (7.6%, n = 1,043)
[Table 1]. Registrations for individual clinicians and units
rose steadily over the study period with a median of
480 (range 237–889) new registrations each month
(Figure 1).
The majority of individual clinician registrants nomi-
nated they were practising in the public hospital setting
(71.1%) and this is where most unit registrations were
also located (69.4%). Most of the individual and unit reg-
istrations originated from the state of NSW (40.0% and
36.2% respectively) [Table 1].
The largest individual clinician group was nursing
(46.7%) followed by medical doctors (19.7%), pharma-
cists (13.9%), and radiation therapists (5.1%). Approxi-
mately half of individual clinicians had less than five
Table 1 Characteristics of eviQ Australian health professional registrants at the end of the observation period
(December, 2011)
Unit registration 1,043(7.6) Individual clinician 12,668(92.4)
n(%) n(%)
Health setting Primary health 212(20.3) 3,009(23.8)
Hospital 831(79.7) 9,659(76.3)
Health sector Public 724(69.4) 9,005(71.1)
Private 259(24.8) 2,259(17.8)
Both 33(3.2) 632(5.0)
Not specified 27(2.6) 772(6.1)
Location New South Wales 378(36.2) 5,065(40.0)
Victoria 236(22.6) 2,577(20.3)
Tasmania 41(3.9) 405(3.2)
Australian Capital Territory 12(1.2) 280(2.2)
Queensland 212(20.3) 2,427(19.2)
South Australia 79(7.6) 856(6.8)
Western Australia 73(7.0) 873(6.9)
Northern Territory 12(1.2) 181(1.4)





Professional experience < 5 years - 6,348(50.1)
5 – 10 years - 1,608(12.7)
> 10 years - 2,756(21.8)
Not specified - 1,956(15.4)
Source of referral to eviQ Peer/colleague - 7,899(62.4)
eviQ Education session - 877(6.9)
Conference/Booth - 409(3.2)
Internet search - 583(4.6)
Cancer Institute communication - 1,401(11.1)
Professional organisation - 985(7.8)
Other - 481(3.8)
Not specified - 33(0.3)
aOther: Academic, Allied Health, Clinical Information Manager, Medical Physicist, ‘Other- not specified’.
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and 18.9% had 2–5 years’ experience). The most com-
mon eviQ referral sources were colleagues (62.4%),
followed by Cancer Institute NSW communications
(11.1%). Unit registrations are likely to represent a group
of health professionals with varying years of clinical ex-
perience. As such, we did not report further on these
registrations.
Patterns of eviQ use
In a typical month (October 2011) there were a total of
169,647 webhits, 86.5% of which occurred duringstandard clinic hours (08:00–18:00; Monday to Friday).
The volume of webhits was generally proportional to the
number of registrations, with the largest registrant groups
having the largest number of hits [Figures 2 and 3].
Not surprisingly, units had more than three times the
webhit rate of individual clinicians (4,997 hits/100 versus
1,159 hits/100 site registrations) [Figure 2]. Further,
pharmacists had at least 1.4 and up to three times the
webhit rate (1,962 hits/100 site registrations) of other
clinical groups such as medical doctors, nurses, and ra-
diation therapists (1,373, 885 and 653 hits/100 site regis-
trations, respectively) [Figure 3].
Figure 1 Cumulative eviQ registrations from October 2009 through December 2011. A) Number of registrations for all individual clinicians
and units; B) Number of registrations for the four largest groups of individual clinicians: medical, nursing, pharmacy, and radiation therapy.
Figure 2 eviQ webhits by time of day for individual clinicians and unit registrations in October 2011. A) Raw webhits; B) Rates of use: hits
per 100 eviQ registrants (clinician or unit). Individual clinicians include medical, nursing, pharmacy, and radiation therapy.
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Figure 3 eviQ webhits by time of day for the largest individual clinician groups in October 2011. A) Raw webhits; B) Rates of use: hits per
100 individual clinicians. Individual clinicians include medical, nursing, pharmacy, and radiation therapy.
Table 2 Profile of the 100 most commonly accessed eviQ
pages in October 2011
Page type n Page views Median time (range)
General pages
Login/registration 7 59,742 00:50 (00:26–01:53)
Transition 45 62,746 00:31 (00:11–01:46)
Total 52 122,488 00:31 (00:11–01:53)
Cancer treatment content pages
Protocols 39 16,483 02:27(00:51–04:46)
Supportive/Other 9 3,566 02:23 (00:28–02:51)
Total 48 20,049 02:27(00:28–04:46)
Total (top 100 pages) 100 142,537 00:57 (00:11–04:46)
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clinicians with 5–10 years’ experience had 1.5 times the
webhit rate of clinicians with less than 5 years’ experience
(1,817 versus 1,184 hits/100 site registrations) and 1.4
times that of clinicians with more than 10 years of experi-
ence (1,817 versus 1,284 hits/100 site registrations).
Typical user sessions
In October 2011, there were 20,611 eviQ site visits,
7,458 of which were by unique visitors. A typical visit
was 7 minutes 33 seconds in duration and 9 pages were
viewed. Most visits were accessed from a computer
(99%, n = 20,326), with the remainder via a mobile de-
vice (1%, n = 285).
Content accessed
In October 2011, there were 184,812 eviQ page views.
This figure, based on Google Analytics page views,
reflects data from all registrants which is why it is
marginally higher than the total eviQ webhits quoted
previously. The latter includes data from medical, nurs-
ing, pharmacy, radiation therapy and unit webhits only.
The top 100 pages visited accounted for 77% (n = 142,
537) of all page views. With respect to page content, 7
were registration/login pages, 45 were transition pages
(such as tabs directing users to specific content) and the
remaining 48 were cancer treatment pages [Table 2].Registration/login and transition pages accounted for
85% (n = 122, 488) of the top 100 page views.
Users spent nearly five times longer on cancer treat-
ment content pages (median 02:27, range 00:28–04:46)
compared to registration/login and transition pages
(median 00:31, range 00:11–01:53) [Table 2].
The most commonly accessed content pages (exclud-
ing login and transition pages) were medical oncology
protocols (64/top 100 content pages); these were repre-
sentative of the most common cancer types [Table 3].
Haematology (16/100) and supportive treatment (18/
100) pages were also frequently accessed; supportive
treatment pages included drug calculators, patient
Table 3 The 100 most commonly accessed cancer treatment content pages in October 2011
Medical oncology (n = 64) n Median (range) page views/protocol Total page views
Breast 18 343 (138–1143) 7,770
Colorectal 19 238 (144–720) 5,879
Respiratory 11 163 (140–714) 2,783
Gynaecological 5 195(140–318) 1,014
Upper Gastrointestinal 5 235(158–515) 1,388
Other solid tumor 6 198 (156–279) 1,230
Haematology (n = 16)
Leukaemias 4 177 (154–263) 770
Lymphomas 9 221(146–415) 2,155
Myeloma 3 241 (150–299) 690
Radiation oncology (n = 2)
Radiation oncology protocols 2 145.5(140–151) 291
Supportive treatment & other (n = 18)
Drug calculators 2 380(258–502) 760
Management of side effects 7 288(148–694) 2,108
Patient information 3 155(147–211) 513
Other 6 289 (145–432) 1,705
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antiemetic regimens, extravasation management, neutro-
penia management).
Discussion
eviQ is an oncology protocol system that has been rated
among the highest quality web-based oncology applica-
tions internationally [5,15]. This paper details a compre-
hensive examination of the uptake and patterns of eviQ
use by healthcare professionals. Despite the increasing
popularity of systems of this kind, this is the first study
to explore the way in which clinicians are using web-
based oncology resources.
Our study demonstrates eviQ is used by the key pro-
fessional groups involved in oncology care. Currently,
we are unable to ascertain the proportion of the oncol-
ogy workforce registered with eviQ due to an absence of
comprehensive data on the number of health care pro-
fessionals employed in oncology practice in Australia.
However, the distribution of health professional registra-
tions by state is directly comparable to the proportion of
cancer cases by state which suggests that eviQ has been
adopted by clinicians nationwide [16]. This is promising
in terms of the potential impact of eviQ on cancer treat-
ment delivery across Australia.
The uptake of eviQ is not surprising given our previ-
ous research showing the system is perceived by
Australian clinicians to provide high quality support for
the full spectrum of cancer care [11]. The system also
rates highly in terms of usability and applicability of pro-
tocols to clinical practice [13,14]. Our finding that the
majority of registrants were referred to eviQ by theirpeers and colleagues is consistent with our previous
work and demonstrates that the website is highly
regarded by its users [11,12,17]. Our logfile analyses sug-
gests that eviQ is used by clinicians at the point-of-care
for cancer treatment delivery as most web activity
(across all professional groups) occurred during standard
clinic hours. Moreover, clinicians spent more time view-
ing specific chemotherapy protocols compared to other
content and the cancer protocols represented the cancer
burden for which chemotherapy is the standard of care
(breast, colorectal, and respiratory cancers) [16,18].
Clearly, not all web traffic during standard clinic hours
will relate directly to point-of-care treatment and our
previous research has shown eviQ is used around the
clock as a reference tool to prepare for clinics and re-
search various treatment options [11,12].
Importantly, we found differences in the rates of eviQ
use by health professional role and years of oncology ex-
perience. We found higher rates of use for oncology
units compared with individual clinicians. This reflects
real world clinical practice where numerous clinicians
access the same computer and use a sole unit login dur-
ing oncology clinics and the delivery of cancer treat-
ment. Additionally, while pharmacists comprised one of
the smallest individual clinician groups, they had the
highest rates of use of any professional group. The more
frequent use by pharmacists is likely due to their roles
in the oncology treatment process: checking prescrip-
tions/dose calculations and answering prescribing re-
lated questions on behalf of the multi-disciplinary team
[11]. Additionally, clinicians with 5–10 years’ oncology
experience (across all professional groups) had the
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perience). It is highly likely clinicians with 5–10 years of
experience are those working most actively at the point-
of-care and making treatment decisions with less experi-
enced staff working under their guidance. Further, our
previous qualitative work demonstrated that the most
senior oncology clinicians were the least reliant on eviQ
to guide their practice [11].
In addition to better understanding the way in which
different professional groups use eviQ our evaluation
also highlights the utility of exploring use in multiple
ways and the strengths and limitations of using specific
indicators of use. To date crude webhits have been the
standard eviQ metric. While this is a good indicator of
the high level of web traffic, it tells little about the spe-
cifics of use. In contrast, rates are a valuable metric that
allow for comparisons between different user groups.
Our rate analyses could give the impression that individ-
ual level use is relatively low (an average of only 12 hits
per month), however, one of the key limitations of our
current analyses is the inability to examine the inter-
registrant variability or to stratify analyses by frequent
and non-frequent eviQ users.
The Google Analytics metrics (which account for extent
of use) provide further detail on the content and time
spent on eviQ during a typical session. However, logfile
analyses are necessarily limited and should not be
interpreted in isolation. Our program of work has made
best use of other methodologies to address important
questions relating to the use of computer support systems
in oncology including system quality and clinicians per-
ceptions about the utility of these systems [5,11,12,15].
Conclusions
Our study has shown eviQ is used widely, registrations
continue to grow and the system is becoming an integral
part of Australian oncology practice. Globally, it is re-
cognised that the number of cancer cases will increase,
so too will the number of available treatments, placing
higher demands on the oncology workforce delivering
care [19]. As such, systems like eviQ are likely to play a
more significant role in the safe and effective administra-
tion of cancer treatments. Ongoing monitoring and eval-
uations are pivotal to understanding the contribution of
web-based decision support systems in promoting effi-
cient service delivery, standardizing care and improving
patient outcomes.
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